Boehringer Ingelheim has forged a co-development and license agreement worth $160m (£128.8m) with science-based company Inflammasome Therapeutics to develop up to three new therapies for retinal diseases.
Ironwood Pharmaceuticals, a GI healthcare company, announced today that it has amended its collaboration agreement with AstraZeneca for the development and commercialization of LINZESS in China.
Accenture has announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its drug development processes.
Lundbeck has agreed to acquire clinical-stage biopharmaceutical company Alder BioPharmaceuticals in a deal valued at around $1.95bn (£1.56bn).
Aytu BioScience, a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs and Innovus Pharmaceuticals, a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer health products, announced that the companies have signed a definitive merger agreement whereby Aytu will retire all outstanding common stock of Innovus for an aggregate of up to $8 million in shares of Aytu common stock, less certain deductions, at the time of closing.
Hansoh Pharmaceutical Group Company, a leading biopharmaceutical company in China, and Atomwise, the leader in artificial intelligence (AI) for drug discovery, have announced a collaboration to design and discover potential drug candidates for up to eleven undisclosed target proteins in multiple therapeutic areas.
Avalon Ventures announced that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK.
UK-based biopharmaceutical company Mallinckrodt has agreed to sell its wholly-owned subsidiary BioVectra to an affiliate of H.I.G. Capital for around $250m (£202m).
Veralox Therapeutics, a preclinical stage company focused on accelerating the development of first-in-class therapeutics for unmet medical needs, has raised a $5.4 million seed funding round.
Japan-based Sumitomo Dainippon Pharma is set to take ownership of the stakes held by Roivant Sciences across five biopharma companies (Vants) in a deal worth $3bn (£2.43bn).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.